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  In the present work, we studied the structure-activity relationship (SAR) of tautomycetin (TMC) 
and its derivatives. Further, we demonstrated the correlation between the immunosuppressive fuction, 
anticancer activity and protein phosphatase type 1 (PP1) inhibition of TMC and its derivatives. We 
have prepared some TMC derivatives via combinatorial biosynthesis, isolation from fermentation broth 
or chemical degradation of TMC. We found that the immunosuppressive activity was correlated with 
anticancer activity for TMC and its analog compounds, indicating that TMC may home at the same 
targets for its immunosuppressive and anticancer activities. Interestingly, TMC-F1, TMC-D1 and 
TMC-D2 all retained significant, albeit reduced PP1 inhibitory activity compared to TMC. However, 
only TMC-D2 showed immunosuppressive and anticancer activities in studies carried out in cell lines. 
Moreover, TMC-Chain did not show any significant inhibitory activity towards PP1 but showed strong 
growth inhibitory effect. This observation implicates that the maleic anhydride moiety of TMC is 
critical for its phosphatase inhibitory activity whereas the C1-C18 moiety of TMC is essential for the 
inhibition of tumor cell proliferation. Furthermore, we measured in vivo phosphatase activities of PP1 
in MCF-7 cell extracts treated with TMC and its related compounds, and the results indicate that 
the cytotoxicity of TMC doesn’t correlate with its in vivo PP1 inhibition activity. Taken together, our 
study suggests that the immunosuppressive and anticancer activities of TMC are not due to the 
inhibition of PP1. Our results provide a novel insight for the elucidation of the underlying molecular 
mechanisms of TMC’s important biological functions.
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INTRODUCTION
  Tautomycetin (TMC) is classified as a type I PKS-derived 
compound which was first isolated in 1989 from Strepto-
myces griseochromogenes, a gram-positive mycelia bacte-
rium [1]. It was originally described as an antifungal 
antibiotics. However, TMC was later found to be able to 
specifically inhibit protein phosphatase type 1 (PP1) and 
protein phosphatase type 2A (PP2A) [2]. In contrast to oth-
er naturally occurring PP1 and PP2A inhibitors, such as 
okadaic acid, calyculin-A, fostriecin, and cantharidin, TMC 
exhibits a high degree of PP1 selectivity [3-5]. TMC prefer-
entially inhibits PP1 by a nearly 40-fold relative to PP2A 
and is the most selective PP1 inhibitor reported to date [2]. 
Furthermore, since TMC is a linear aliphatic inhibitor of 
PP1, and not a cyclic peptide like microcystins and nodular-
ins [6,7], it is an attractive lead compound for novel 
PP1-specific drug design.
  The protein phosphatase PP1 is tightly regulated by its 
interaction with more than 180 known targeting proteins 
which localize PP1 and its inhibitory proteins to distinct 
regions of the cell [8,9]. The broad spectrum of PP1 binding 
partners is consistent with the wide distribution of PP1 
throughout the human body and its multiple regulatory 
roles in cellular processes such as cell-cycle progression, 
protein synthesis, muscle contraction, carbohydrate metab-
olism, transcription and neuronal signaling. Given the im-
portance of the interplay between phosphatases and kin-
ases in human diseases, the selective inhibition of PP1 and 
PP2A has been proposed to be an attractive goal for rational 
anticancer drug design [10]. 
  TMC represents not only an interesting drug lead but 
also a powerful biochemical tool to elucidate the roles of 
PP1 in various biological pathways. TMC has been sug-146 M Niu, et al
gested as a potential drug for colorectal cancer chemo-
therapy because of its regulation of Raf-1 activity in a colon 
cancer cell-type-specific manner. The anti-proliferation ef-
fect of TMC on human colon cancer cell lines is found to 
be accompanied by induction of the level of cell cycle regu-
lator p21
Cip/WAF1 through the Raf/ERK pathway. Although 
TMC treatment led to activation of the Raf-1-MEK-ERK 
cascade, the level of GTP-bound Ras was not altered, in-
dicating that TMC may mediate its effects through regu-
lation of Raf-1 activity [11].
  TMC has been also identified as a potent immuno-
suppressor of activated T cells both in vitro and in vivo [12]. 
Inhibition of T cell proliferation by TMC was observed at 
concentrations 100-fold lower than those needed to achieve 
maximal inhibition by cyclosporine A (CsA). CsA and 
FK506 exert their pharmacological effects by binding to the 
immunophilins; the resulting complex binds to and inhibits 
the Ser/Thr phosphatase calcineurin albeit with potentially 
deleterious effects due to the physiological ubiquity of calci-
neurin [13,14]. TMC exerts immunosuppressive activity in 
a manner completely different from those of CsA and 
FK506 by blocking tyrosine phosphorylation of T-cell-specif-
ic signaling mediators. This leads to cell-specific apoptosis 
due to cleavage of Bcl-2, caspase-9, caspase-3, and poly 
(ADPribose) polymerase. The activated T cell specificity of 
TMC thus suggests this unique polyketide as a significant 
lead in the search for immunosuppressive drugs superior 
to CsA and FK506 [12].
  The immunosuppressive and anticancer activities of TMC 
are both thought to be related to its ability to inhibit protein 
phosphatases. Unfortunately, this hypothesis has not yet 
been fully clarified. On the other hand, it is of importance 
to gain more insights into its structure-activity relationship 
due to the increasing use of TMC as a biological probe in 
molecular and cellular biology. In the present study, the 
biological activities of TMC and its derivatives were exam-
ined, and the interrelationship between the biological activ-
ities and the chemical structures was discussed. 
METHODS
Generation of TMC mutant strains
  The tauF, tauD and tauK genes were inactivated using 
a PCR-targeted gene-disruption system according to the lit-
erature protocols [15]. Briefly, an apramycin resistance 
gene aac(3)IV/oriT cassette was used to replace an internal 
region of each target gene. Mutant cosmids pTAUTF (Δ
tauF), pTAUTD (ΔtauD) and pTAUTK (ΔtauK) were con-
structed and introduced into S. griseochromogenes by con-
jugation from E. coli ET12567/pUZ8002 according to the 
literature procedure illuminated the part of conjugation 
procedure above. The desired double crossover mutants, se-
lected by the apramycin-resistant and kanamycin-sensitive 
phenotype, were isolated as STQF (ΔtauF), STQD (ΔtauD) 
and STQK (ΔtauK). 
Extraction of TMC and its derivatives
  TMC and TMC-OH were isolated from the fermentation 
broth of wild strain, while TMC-F1, TMC-D1, TMC-D2, 
TMC-K1 and TMC-K2 were isolated from the fermentation 
broth of ΔtauF, ΔtauD, ΔtauK mutant strains respectively. 
TMC-Ring and TMC-Chain were obtained by chemical deg-
radation of TMC with CsCO3. All these compounds were 
analyzed and purified by HPLC with CH3CN / H2O (0.5% 
acetic acid) as mobile phase. Compound identity was con-
firmed by high-resolution mass spectrometry and no im-
purities were detected by 
1H-NMR.
Animals and cell culture
  Female Balb/c mice between 8 and 14 weeks of age were 
housed under SPF conditions. The experimental procedure 
was reviewed and approved by the Dalian University of 
Technology Animal Research Committee. The Jurkat T cell, 
MCF-7 human breast cancer cell line and HCT-15 human 
colon cancer cell line were maintained in the RPMI 1640 
medium containing 10% fetal bovine serum, antibiotics (100 
U penicillin/ml and 100 μg streptomycin/ml), and 1.5 mM 
L-glutamine at 37°C in a 5% CO2 humidified incubator.
Cell proliferation assay
  MCF-7 and HCT-15 tumor cell proliferation was meas-
ured by 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazo-
lium bromide (MTT) rapid colorimetric assay [16]. Briefly, 
cells were seeded in quadruplicate on 96-well plates and 
incubated overnight under standard conditions to allow cell 
attachment. The cells were then treated with TMC and its 
derivatives at concentrations of 0 to 100 μM and incubated 
for up to 72 hours. The MTT assay was performed by replac-
ing the standard medium with 100 μl PBS containing 0.5 
mg/ml MTT and incubating at 37
oC for 4 hours. After in-
cubation, the crystals were dissolved with 200 μl dimethyl 
sulfoxide. The multiwell plates were then measured at 540 
nm using a spectrophotometer (Molecular Devices).
Assay of PP1 phosphatase activity
  The activities of PP1 was assayed with 6,8-difluoro-4- 
methylumbelliferyl phosphate (DiFMUP) as a substrate 
(EnzChek phosphatase assay kit, Invitrogen, Madison, WI). 
Briefly, recombinant PP1 (NEB) was diluted with reaction 
buffer (50 mM HEPES, 100 mM NaCl, 1 mM MnCl2, 2 mM 
DTT, 0.01% Brij-35), then preincubated with TMC or its 
derivatives for 20 min at 30
oC. The substrate for PP1 was 
added and samples were incubated at 30
oC in a shaking 
incubator for 30 min. Then phosphatase activity was meas-
ured in a fluorometer using excitation at 360 nm and emis-
sion detection at 460 nm. For in vivo PP1 phosphatase as-
says, MCF-7 cells were grown to subconfluence in 100-mm 
dishes with or without TMC or its derivatives for 4 h at 
37
oC. Thereafter, growth media were removed from control 
or drug-treated cultures, which were then washed twice 
with phosphate-buffered saline. Following this, 0.2 ml of 
lysis buffer (20 mmol imidazole-HCl, 2 mmol EDTA, 2 
mmol EGTA with 10 μg/ml each of aprotinin, leupeptin, 
pepstatin, 1 mmol benzamidine, and 1 mmol phenyl-
methylsulfonyl fluoride) was added to each dish. Cells were 
scraped into a plastic tube and centrifuged at 10,000 g and 
4
oC for 10 min to give a soluble supernatant. Lysates were 
incubated with an additional 2 nM or 100 nM okadaic acid 
for 15 min before the labeled substrates were added. PP1 
activity is defined as the activity insensitive to 2 nM oka-
daic acid but inhibited by 100 nM okadaic acid. Subse-
quently, the supernatants were assayed for PP1 activities 
using a phosphatase assay kit as described above for the 
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Fig. 1. Structure of TMC and its analogous compounds.
T cell proliferation assay and IL-2 ELISA
  Primary T cells were isolated from the spleen of mice. 
Two spleens were converted into single-cell suspensions by 
squeezing through a cell strainer with the rough end of a 
3-ml syringe plunger. Cells were spun down in a 50-ml 
Falcon tube (5 min, 300 ×g) and the supernatant was 
discarded. The pellet was vigorously resuspended in eryth-
rocyte lysis buffer (5 ml/spleen) and then incubated for 5 
min at room temperature. The mixture was filled up with 
PBS to 30 ml, spun down (5 min, 300 ×g) and resuspended 
in 5 ml PBS. Sequentially, CFSE was added at 10 μm/ml 
for labeling at room temperature for 5 min, followed by add-
ing 25 ml RPMI containing 10% FCS, spin at same as 
above. CFSE used for labeling of the CD4 and CD8 T cells 
to monitor the proliferation. Cells were counted and re-
suspended at 5×10
6 per ml containing 50 U/ml human IL-2. 
Next, the T cells were placed into the plates coated with 
anti-CD3 and -CD28 Ab at 100 μg/ml and 50 μg/ml 
respectively. The cells were incubated in 48 well-plates for 
3 days. The CD4 and CD8 T cells were analyzed by FACS 
method. The function of compounds will be determined by 
CFSE dilution of cell contents. 
  For viability assay of Jurkat T cell, the cells were treated 
with TMC and its derivatives at concentrations of 0 to 100 
μM and incubated for up to 72 hours. Cell viability was 
determined using a Cell Proliferation Assay kit (Promega, 
USA). The MTS assay is a colorimetric method that uses 
a tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS), and an electron-coupling reagent, phenazine metho-
sulfate (PMS). The cells chemically reduce MTS into for-
mazan, which is soluble in tissue culture medium. MTS was 
then added to each well and the plates were read at 490 
nm wavelength three hours later using an ELISA reader 
(Molecular Devices).
  Jurkat T cell IL-2 cytokine levels in conditioned medium 
were determined using a commercial ELISA kit. It detects 
soluble IL-2 with a monoclonal antibody specific for IL-2. 
Briefly, the monoclonal antibody will bind IL-2 in cell cul-
ture supernatants during incubation. After several washes 
to remove unbound proteins, an enzyme-linked polyclonal 
antibody was added that binds to the solid phase bound 
IL-2. After washing, the substrate solution was added and 
developing color was measured using a multiwell plate 
reader set to 450 nm. The optical density of the samples 
was compared to a calibration curve.
Data analysis
  The results were statistically analyzed using one-way 
ANOVA and considered statistically significant at the p＜ 
0.05 level. Data with standard deviations of three in-
dependent experiments with three to five replicates each 
were presented. 
RESULTS
Structure of TMC and its analogous compounds
  As the most specific inhibitor of protein phosphatase 1 
in vitro, TMC has been reported to have anti-fungi, anti-tu-
mor and immunosuppressive activities [2,12], which make 
TMC and its analogs excellent agents for potential clinical 
use as well as for biological studies. To dissect the relation-
ship between protein phosphatase inhibition and other bio-
logical functions of TMC, we obtained a series of TMC ana-
log compounds via genetic engineering of the TMC bio-
synthetic gene cluster, by isolation from fermentation 
broth, or through chemical degradation. The structures of 
the compounds used in this study are shown in Fig. 1. 
Compared with TMC，TMC-OH lacks the hydroxyl group 
at the C3’ position. TMC-F1, TMC-D1 and TMC-D2 all lack 
the terminal C3 olefin, a critical feature of the right hemi-
sphere of TMC. TMC-F1 and TMC-D2 have β-hydroxy-
propanoic acid and acrylic acid attached to C3 position 
respectively. TMC-D1 lacks carbonyl group at the C5 posi-
tion and has an acrylic acid attached to C3. Both TMC-K1 
and TMC-K2 lacks carbonyl group at the C5 position com-
pared to their parent structures TMC and TMC-OH. Lastly, 
TMC-Ring possesses only the dialkymalic anhydride moiety 148 M Niu, et al
Fig. 2. Effects of TMC and its analogous compounds on inhibition 
of recombinant PP1 activity. 2 U/ml of recombinant PP1was 
preincubated with or without indicated concentrations of TMC or 
its derivatives for 20 min at 30
oC, and phosphatase activities were 
measured as described in materials and methods.
Table 1. IC50  Values of TMC and its related compounds for the 
catalytic subunits of PP1
Compounds IC50 (nM)
TMC    0.54±0.03
TMC-OH  200±12
TMC-F1  28±8
TMC-D1 101±7
TMC-D2  610±40
TMC-K1      16±0.43 
TMC-K2 2,090±86
TMC-Ring  9,854±280
TMC-Chain  32,150±1,892
Table 3. Summary of in vitro cytotoxicity data for TMC and 
its related compounds against primary T cells
Compounds 200 μM2 0   μM2   μM0 . 2   μM
Folds/ 
TMC
TMC ×× ×× × ＋ 1
TMC-OH ×× ＋＋ ＋ ＋ 35
TMC-F1 × ＋＋ ＋ ＋ ＋ 100
TMC-D1 × ＋＋ ＋ ＋ ＋ 100
TMC-D2 ×× × ＋＋ ＋ 10
TMC-K1 ×× × ＋＋ ＋ 10
TMC-K2 × ＋＋ ＋ ＋ ＋ 100
TMC-Ring × ＋＋ ＋ ＋ ＋ 100
TMC-Chain ×× × ＋＋ ＋ 20
The sign X and ＋ indicate primary T cells dead and live, 
respectively.
Table 2. Summary of in vitro cytotoxicity data for tautomycetin 
and its related compounds against human cancer cell lines
Compounds
IC50 ( μM)
HCT-15 MCF-7
TMC 0.35±0.04 0.4±0.04
TMC-OH 13±1.6 17±1.8
TMC-F1 >50 >50
TMC-D1 >50 >50
TMC-D2  8±0.7 10±0.6
TMC-K1  8±0.6   9±0.8
TMC-K2 >50 >50
TMC-Ring >50 >50
TMC-Chain 10±0.6 12±0.9
whereas TMC-Chain possesses only a carbon chain.
Effect of TMC and its related compounds on PP1 
activity
  We then set to determine the effect of the structural 
changes on inhibition of PP1 activity. As shown in Fig. 2, 
TMC and its related compounds inhibited activities of the 
catalytic subunits of PP1 with a wide range of IC50 values 
(from 0.5 nM to 40 μM). The magnitude of the inhibitory 
activity was in the order of TMC ＞ TMC-K1 ＞ TMC-D1 
≈  TMC-F1  ≈  TMC-OH  ＞  TMC-D2  ＞  TMC-K2  ＞ 
TMC-Ring ＞ TMC-Chain. Table 1 shows the IC50 values 
of all compounds examined. The IC50 v a l u e s  o f  T M C - K 1 ,  
TMC-D1, TMC-F1, TMC-OH and TMC-D2 were estimated 
to be 16 nM, 101 nM, 128 nM, 200 nM and 610 nM 
respectively. Among all the TMC derivatives, TMC-Chain 
demonstrates the lowest IC50 values of 32 μM against PP1. 
Effects of TMC and its related compounds on anti-
cancer activity
  We evaluated the cytotoxicity of TMC and its related 
compounds against HCT-15 colon adenocarcinoma and 
MCF-7 breast carcinoma cell lines. The IC50 values of TMC 
and its related compounds for inhibition of cancer cell 
growth are summarized in Table 2. TMC, TMC-OH, 
TMC-D2, TMC-K1 and TMC-Chain inhibited the growth of 
HCT-15 cells with IC50 values of 0.35 μM, 13 μM, 8 μM, 
8 μM and 10 μM respectively. The IC50 values of the rest 
of the compounds (TMC-F1, TMC-D1, TMC-K2 and TMC- 
Ring) are all beyond 50 μM. The IC50 values of TMC and 
its derivatives for inhibiting MCF-7 cells growth were al-
most the same as those for inhibiting HCT-15 cells growth.
Effects of TMC and its related compounds on immuno-
suppressive function
  TMC  exhibits  its  immunosuppressive activity via T 
cell-specific apoptosis induction. We evaluated the cytotox-
icity of TMC and its related compounds against primary 
T cells (Table 3). While the analogs TMC-F1, TMC-D1, 
TMC-K2 and TMC-Ring did not show any inhibitory effect 
at concentrations below 20 μM, TMC-OH, TMC-K1 and 
TMC-Chain retained significant, albeit reduced, cytoxicity 
(within 35-fold of reduction relative to TMC). Cytotoxicity 
of TMC and its related compounds against Jurkat T cell 
lines was also evaluated (Table 4). TMC, TMC-OH, TMC- 
D2, TMC-K1 and TMC-Chain inhibited the growth of 
Jurkat T cells with IC50  values of 0.28 μM, 18.2 μM, 10 
μM, 5.4 μM and 9.6 μM respectively. The IC50 values of 
the rest of the compounds (TMC-F1, TMC-D1, TMC-K2 and 
TMC-Ring) are beyond 50 μM. Remarkably, production of 
IL-2 was almost completely suppressed (98%) by TMC (200 
nM), TMC-OH, TMC-D2, TMC-K1 and TMC-Chain (20 μM). Differential Effects of Tautomycetin and Its Derivatives 149
Table 4. Summary of in vitro cytotoxicity data for TMC and 
its related compounds against Jurkat T cell lines
Compounds IC50 ( μM)
TMC  0.28±0.02
TMC-OH 18.2±1.3
TMC-F1 >50
TMC-D1 >50
TMC-D2 6.8±0.3
TMC-K1 5.4±0.5
TMC-K2 >50
TMC-Ring >50
TMC-Chain 9.6±0.4
Fig. 4. Effects of TMC and its analogous compounds on the viability 
of MCF-7 cells and in vivo PP1 phosphatase activities in MCF-7 
cells. (A) To measure in vivo PP1 activity, MCF-7 cells were treated 
with indicated concentrations of TMC, TMC-F1 or TMC-Chain for 
4 h and cell lysates were assayed for phosphatase activities of PP1 
as described in materials and methods. (B) MCF-7 cells were 
treated with the indicated concentrations of TMC, TMC-F1 or 
TMC-Chain for 48h. Cell viability was determined by an MTT 
colorimetric growth assay. The sign * indicates difference (p<0.05) 
compared to control.
Fig. 3. Effects of TMC and its related compounds on cytokine IL-2 
secretion. Jurkat T cells (1×10
6 cells/ml) were pretreated with TMC 
(0.2 μM) or its analogous compounds (20 μM), and then stimulated 
with anti-CD3 mAb (10 μg/ml) and anti-CD28 mAb (0.5 μg/ml) at 
37
oC for 24 h. IL-2 cytokine levels in conditioned medium were 
determined using a ELISA kit. Data are expressed as percent of 
control. The sign * indicates difference (p＜0.05) compared to control.
In contrast, TMC-F1, TMC-D1, TMC-K2 and TMC-Ring did 
not show significant inhibition of IL-2 production in the 
same range of concentrations (Fig. 3).
Cytotoxicity of TMC doesn’t correlate with its in vivo 
PP1 inhibition activity
  To further investigate the relationship between cytotox-
icity of TMC and its PP1 inhibitory activity, we measured 
in vivo phosphatase activity of PP1 in MCF-7 cell extracts 
treated with TMC and its related compounds (Fig. 4A). 
TMC (1 and 2 μM) decreased PP1 activities by 60% and 
81% compared to untreated cells, respectively. The cell 
growth exposed to 1 and 2 μM TMC were inhibited by 90% 
and 96% relative to untreated cells (Fig. 4B). The PP1 activ-
ities treated with 20 and 50 μM TMC-F1 were also reduced 
by 38% and 60%, respectively. In contrast, TMC-F1 did not 
significantly affect the growth of MCF-7 cells with the in-
hibition ratio of 8% and 24%, respectively. In vivo activities 
of PP1 in extracts prepared from TMC-Chain (20 and 50 
μM)-treated cells were only reduced by 9% and 19% 
respectively. However, TMC-Chain significantly affected 
the growth of MCF-7 cells, with a decrease of 70% and 89% 
respectively. These results indicate that the cytotoxicity of 
TMC doesn’t correlate with its in vivo PP1 inhibitory 
activity.
DISCUSSION
  We have studied the relationship between the chemical 
structure and the function of TMC and its derivatives. Our 
results could provide new insight into the relationship of 
protein phosphatase inhibition with cell killing capacity. 
  To investigate the impact of right hemisphere mod-
ification upon TMC bioactivity, TMC related compounds 
were subjected to PP1 inhibition and cytotoxicity assays. 
The results showed that immunosuppressive activity was 
accordant with anticancer activity for TMC and its analog 
compounds. For instance, the IC50 values for inhibiting 
MCF-7 cell growth are accordant with inhibiting Jurkat T 
cell growth for all TMC derivatives. These results indicate 
that TMC may home at the same targets for its im-
munosuppressive and anticancer activity. TMC-F1 and 
TMC-D1 both retained significant, albeit reduced, PP1 in-
hibitory activity, while the two compounds did not show 
immunosuppressive and anticancer activity. TMC-OH 
showed significant immunosuppressive and anticancer ac-
tivity, with potent PP1 inhibitory activity similar to 150 M Niu, et al
TMC-F1 and TMC-D1. TMC-D1 and TMC-D2 are structur-
ally similar, differing only in the presence of a carbonyl 
group at the C5 position on TMC-D2. TMC-D1 had a more 
significant PP1 inhibitory activity than that of TMC-D2, 
whereas it showed less cytotoxicity. Moreover, TMC-Chain 
did not show any significant inhibitory activity for PP1 but 
similarly showed strong growth inhibitory effect. This fact 
demonstrates that the maleic anhydride moiety of TMC is 
critically important for its phosphatase inhibitory activity 
but not for its growth inhibitory effect, whereas the C1-C18 
moiety of TMC is essential for the inhibition of cell 
proliferation. 
  In order to further confirm the relationship between cyto-
toxicity of TMC and its PP1 inhibitory activity, we meas-
ured in vivo phosphatase activities of PP1 in MCF-7 cell. 
The  in vivo PP1 activities treated with TMC-F1 and 
TMC-Chain (50 μM) were reduced by 60% and 19%, 
respectively. In contrast, growth of cells exposed to the 
same concentration of TMC-F1 and TMC-Chain were in-
hibited by 19% and 89% relative to untreated cells, respec-
tively. However, even if the in vivo PP1 inhibitory activity 
was almost completely lost, TMC-Chain (20 μM) showed 
relative potent cytotoxic activity. Moreover, both TMC (2 
μM) and TMC-F1 (50 μM) reduced the PP1 activity by 
60%, whereas the cell viabilities were inhibited by 90% and 
24%, respectively. These results indicate that the cytotox-
icity of TMC does not correlate with its in vivo PP1 in-
hibition activity.
  It has been previously reported that thyrsiferyl 23- ace-
tate and tautomycin exhibit apoptosis-inducing activity in 
addition to their inhibitory effect on protein phosphatase 
[18,19]. Similarly, our studies also demonstrated that TMC 
can inhibit cell growth by inducing apoptosis (data not 
shown) besides its phosphatase inhibitory function. The 
present work provides further evidence that the phospha-
tase-inhibitory activity and the growth inhibitory effect 
could be attributed to different portions of the natural com-
pound. A recent report suggests that SHP2 (Src homology-2 
domain containing protein tyrosine phosphatase-2) is a po-
tential target for the immunosuppressive activity of TMC. 
Specifically, TMC and TMC-D1 inhibit SHP2 with a similar 
IC50 values whereas TMC-D2 does not exhibit significant 
inhibitory activity against SHP2 [20]. However, our data 
demonstrated that TMC-D2, instead of TMC-D1, exhibited 
significant immunosuppressive activity. This is incon-
sistent with the proposed target model. If SHP2 is a cellular 
target for TMC, it can not explain the mechanism for 
TMC-D2’s observed immunosuppressive and anticancer 
activity. In this regard, we do not rule out the possibility 
that TMC’s biological activities could be attributed to its 
interaction with other cellular proteins. Thus, some un-
identified molecular target may be required to explain the 
biological activities of TMC.
  PP1 are critical signaling molecules that regulate many 
cellular processes including cell cycle progression, cell 
growth, gene expression, calcium transport and neuronal 
signaling [21]. Therefore, one prevailing hypothesis is that 
the TMC-induced apoptosis occurs through the inhibition 
of PP1 [11,12]. Remarkably, our study has implicated that 
different portions of TMC structure play a distinct role in 
protein phosphatase inhibition and the induction of 
apoptosis. Our data suggest that the immunosuppressive 
and anticancer activity of TMC is not only due to the in-
hibition of PP1. Therefore, we suggest that TMC may have 
multiple targets for its biological activities. Multiple block-
ades of these molecular targets may produce additive and 
even synergistic cytostatic effects. Identification of poten-
tial novel targets responsible for different effects of TMC 
is underway. 
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